Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study

BACKGROUND: Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Med Sci Monit
Hlavní autoři: Hu, Naibo, Qin, Tiejun, Du, Xiaoyan, Wang, Bingyi, Wang, Xiaoyun, Xu, Zefeng, Pan, Lijuan, Qu, Shiqiang, Xiao, Zhijian
Médium: Artigo
Jazyk:Inglês
Vydáno: International Scientific Literature, Inc. 2021
Témata:
Clinical Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7856837/
https://ncbi.nlm.nih.gov/pubmed/33514682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.928454
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky